1. Home
  2. STX vs NVO Comparison

STX vs NVO Comparison

Compare STX & NVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Seagate Technology Holdings PLC (Ireland)

STX

Seagate Technology Holdings PLC (Ireland)

HOLD

Current Price

$911.62

Market Cap

182.2B

Sector

Technology

ML Signal

HOLD

Logo Novo Nordisk A/S

NVO

Novo Nordisk A/S

HOLD

Current Price

$47.66

Market Cap

197.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
STX
NVO
Founded
1978
1923
Country
Singapore
Denmark
Employees
N/A
69500
Industry
Electronic Components
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
182.2B
197.4B
IPO Year
2002
N/A

Fundamental Metrics

Financial Performance
Metric
STX
NVO
Price
$911.62
$47.66
Analyst Decision
Buy
Hold
Analyst Count
21
11
Target Price
$604.14
$51.00
AVG Volume (30 Days)
3.5M
11.9M
Earning Date
04-28-2026
05-06-2026
Dividend Yield
0.46%
3.19%
EPS Growth
328.48
N/A
EPS
8.29
N/A
Revenue
$7,384,000,000.00
N/A
Revenue This Year
$27.73
N/A
Revenue Next Year
$25.06
$3.70
P/E Ratio
$123.38
$13.60
Revenue Growth
N/A
N/A
52 Week Low
$138.31
$35.12
52 Week High
$1,145.00
$71.80

Technical Indicators

Market Signals
Indicator
STX
NVO
Relative Strength Index (RSI) 48.70 65.41
Support Level $801.89 $47.52
Resistance Level $966.80 $47.79
Average True Range (ATR) 71.82 1.32
MACD -9.29 0.47
Stochastic Oscillator 29.81 87.39

Price Performance

Historical Comparison
STX
NVO

About STX Seagate Technology Holdings PLC (Ireland)

Seagate Technology is a leading supplier of hard disk drives for data storage to the enterprise and consumer markets. It forms a practical duopoly in the market with its chief rival, Western Digital; they are both vertically integrated.

About NVO Novo Nordisk A/S

With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Share on Social Networks: